---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-015170"
form_type: "8-K"
ticker: "MTNB"
cik: "0001582554"
company_name: "Matinas BioPharma Holdings, Inc."
filed_at: "2026-04-03T23:59:59+00:00"
generated_at: "2026-05-15T07:35:52.322086+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Matinas BioPharma receives NYSE American delisting notice for low equity

## Summary
- Stockholders' equity was $4.83M as of Dec 31, 2025, below the $6M threshold for five years of losses.
- Company has until May 2, 2026 to submit a plan to regain compliance; cure period up to 18 months.
- Independent auditor included a going-concern paragraph in the 10-K for the year ended Dec 31, 2025.
- No immediate impact on listing; common stock continues trading on NYSE American pending review.
- If plan is rejected, delisting proceedings will commence; company may appeal per NYSE rules.

## SEC filing metadata
- accession: 0001493152-26-015170
- form_type: 8-K
- ticker: MTNB
- cik: 0001582554
- company_name: Matinas BioPharma Holdings, Inc.
- filed_at: 2026-04-03T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582554/000149315226015170/0001493152-26-015170-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582554/000149315226015170/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-015170
- JSON: https://secwatch.observer/filing/0001493152-26-015170.json
- Plain text: https://secwatch.observer/filing/0001493152-26-015170.txt

## Source-grounded claims
- claim_id: c9654735ecbe72cdb857f15f6e2509c074cfae27
  claim: Matinas BioPharma Holdings, Inc. received a nyse_american deficiency notice notice regarding stockholders equity (rules 1003(a)(i), 1003(a)(ii), 1003(a)(iii)).
  evidence_excerpt: April 2, 2026, Matinas BioPharma Holdings, Inc. (the “Company”) received a written notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) indicating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the “Company Guide”) requiring a company to have stockholders’ equity of at least $2.0 million if it has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years, Section 1003(a)(ii) of the Company Guide requiring a company to ha
  evidence_url: https://www.sec.gov/Archives/edgar/data/1582554/000149315226015170/0001493152-26-015170-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.